Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894940 | 0.97 | TAAR1 (0.47) | TAAR1IDO1AGXTEPHX2AOC3 | |
| SCHEMBL6785733 | 0.80 | IDO1 (0.44) | TAAR1IDO1AGXTAOC3 | |
| SCHEMBL145383 | 0.78 | CHRM2 (0.65) | TAAR1AOC3MTNR1AMTNR1BCHRM2 | |
| SCHEMBL28123652 | 0.77 | CYP1A2 (0.50) | TAAR1IDO1AGXT | |
| SCHEMBL6785971 | 0.77 | TAAR1 (0.46) | TAAR1IDO1AGXTAOC3CHRM2 | |
| SCHEMBL1396277 | 0.77 | TAAR1 (0.46) | TAAR1IDO1AGXT | |
| 1,3-Dimethoxybenzene SCHEMBL28268904 | 0.76 | ACHE (0.44) | TAAR1IDO1AGXTEPHX2MTNR1A | |
| SCHEMBL4817193 | 0.76 | CHRM2 (0.63) | TAAR1MTNR1AMTNR1BCHRM2CHRM1 | |
| SCHEMBL1350580 | 0.75 | DNM1 (0.44) | EPHX2 | |
| SCHEMBL9796229 | 0.75 | PPARG (0.61) | TAAR1EPHX2MTNR1AMTNR1BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | TAAR1 2269/4885IDO1 3237/4885AGXT 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.